Voluntary Medical Male Circumcisions for HIV Prevention - 13 Countries in Eastern and Southern Africa, 2017-2021.


Journal

MMWR. Morbidity and mortality weekly report
ISSN: 1545-861X
Titre abrégé: MMWR Morb Mortal Wkly Rep
Pays: United States
ID NLM: 7802429

Informations de publication

Date de publication:
10 Mar 2023
Historique:
entrez: 9 3 2023
pubmed: 10 3 2023
medline: 14 3 2023
Statut: epublish

Résumé

In 2007, voluntary medical male circumcision (VMMC) was endorsed by the World Health Organization (WHO) and the Joint United Nations Programme on HIV/AIDS after it was found to be associated with approximately a 60% reduction in the risk for female-to-male transmission of HIV (1). As a result of this endorsement, the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), through partnerships with U.S. government agencies, including CDC, the U.S. Department of Defense, and the U.S. Agency for International Development, started supporting VMMCs performed in prioritized countries in southern and eastern Africa. During 2010-2016, CDC supported 5,880,372 VMMCs in 12 countries (2,3). During 2017-2021, CDC supported 8,497,297 VMMCs performed in 13 countries. In 2020, the number of VMMCs performed declined 31.8% compared with the number in 2019, primarily because of COVID-19-related disruptions to VMMC service delivery. PEPFAR 2017-2021 Monitoring, Evaluation, and Reporting data were used to provide an update and describe CDC's contribution to the scale-up of the VMMC program, which is important to meeting the 2025 Joint United Nations Programme on HIV/AIDS (UNAIDS) target of 90% of males aged 15-59 years having access to VMMC services in prioritized countries to help end the AIDS epidemic by 2030 (4).

Identifiants

pubmed: 36893046
doi: 10.15585/mmwr.mm7210a2
pmc: PMC10010757
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

256-260

Déclaration de conflit d'intérêts

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

Références

MMWR Morb Mortal Wkly Rep. 2013 Nov 29;62(47):953-7
pubmed: 24280914
MMWR Morb Mortal Wkly Rep. 2016 Jan 22;65(2):36-7
pubmed: 26797167
MMWR Morb Mortal Wkly Rep. 2017 Dec 01;66(47):1285-1290
pubmed: 29190263
BMJ Open. 2018 Sep 1;8(8):e021835
pubmed: 30173159

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH